Cost-effectiveness of the Recommendations of the Advisory Committee on Immunization Practices for the Recombinant Adjuvanted Zoster Subunit Vaccine
This cost-effectiveness study evaluates use of the recombinant adjuvanted zoster subunit vaccine among patients 50 years and older.
Cost-effectiveness of the Recommendations of the Advisory Committee on Immunization Practices for the Recombinant Adjuvanted Zoster Subunit Vaccine
Source: Virology News